Mechref Yehia, Hu Yunli, Garcia Aldo, Zhou Shiyue, Desantos-Garcia Janie L, Hussein Ahmed
Department of Chemistry & Biochemistry, Texas Tech University, Lubbock, TX 79409-1061, USA.
Bioanalysis. 2012 Oct;4(20):2457-69. doi: 10.4155/bio.12.246.
For decades, the association between aberrant glycosylation and many types of cancers has been shown. However, defining the changes of glycan structures has not been demonstrated until recently. This has been facilitated by the major advances in MS and separation science, which allows the detailed characterization of glycan changes associated with cancer. MS glycomics methods have been successfully employed to compare the glycomic profiles of different human specimens collected from disease-free individuals and patients with cancer. Additionally, comparing the glycomic profiles of glycoproteins purified from specimen collected from disease-free individuals and patients with cancer has also been performed. These types of glycan analyses employing MS or LC-MS allow the characterization of native, labeled and permethylated glycans. This review discusses the different glycomic and glycoproteomic methods employed for defining glycans as cancer biomarkers of different organs, including breast, colon, esophagus, liver, lung, ovarian, pancreas and prostate.
几十年来，异常糖基化与多种癌症之间的关联已得到证实。然而，直到最近才能够确定聚糖结构的变化。质谱（MS）和分离科学的重大进展推动了这一进程，这些进展使得对与癌症相关的聚糖变化进行详细表征成为可能。MS糖组学方法已成功用于比较从无病个体和癌症患者收集的不同人类样本的糖组图谱。此外，还对从无病个体和癌症患者收集的样本中纯化的糖蛋白的糖组图谱进行了比较。这些使用MS或液相色谱-质谱联用（LC-MS）的聚糖分析类型能够对天然、标记和全甲基化聚糖进行表征。本综述讨论了用于将聚糖定义为不同器官（包括乳腺、结肠、食管、肝脏、肺、卵巢、胰腺和前列腺）癌症生物标志物的不同糖组学和糖蛋白质组学方法。
